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Abstract
Invasive pulmonary aspergillosis (IPA) and pneumocystis jiroveci pneumonia (PCP) are life-
threatening opportunistic infections that occur in immunocompromised hosts. Early diagnosis
and treatment of these opportunistic infections is essential to the survival of immunocompromised
patients. We report a 60-year-old man undergoing short-term steroid therapy after surgical resec-
tion of a brain tumor infected with combined invasive pulmonary aspergillosis and pneumocystis
jiroveci pneumonia diagnosed by bronchoscopy with bronchoalveolar lavage. Our case demon-
strated that short-term systemic steroid therapy in non-HIV patients with underlying chronic lung
conditions and malignancies was a risk factor for IPA and PCP, and for a combination of these
infections.
KEYWORDS: pneumocystis jiroveci pneumonia, invasive pulmonary aspergillosis, steroid ther-
apy, pulmonary
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nvasive pulmonary aspergillosis (IPA) is a life-
threatening fungal infection that predominantly 
aﬀ ects severely immunocompromised patients,  par-
ticularly those with prolonged neutropenia,  organ 
transplantation,  or high-dose corticosteroid therapy 
[1,  2].  Pneumocystis jiroveci pneumonia (PCP) is 
also a life-threatening opportunistic infection which 
occurs in immunocompromised hosts,  especially 
patients with acquired immunodeﬁ ciency syndrome 
(AIDS).  PCP is increasing in frequency in other 
immunosuppressed patients,  including organ trans-
plant recipients and those with malignancy who are 
treated with steroids and chemotherapeutic regimens 
[1,  3].  These opportunistic infections are usually 
diagnosed during an autopsy or when it is too late to 
treat them.  A high degree of suspicion is necessary to 
diagnose these infections.  Here,  we describe a fatal 
case of combined IPA and PCP in a patient not 
infected with human immunodeﬁ ciency virus (HIV).
Case Report
　 A 60-year-old man was diagnosed with renal cell 
carcinoma and was treated with nephrectomy in Oct.  
1997.  For 8 years after the operation,  he had been 
generally well without any signs of recurrence.  The 
patient had a history of smoking and chronic obstruc-
tive respiratory disease (COPD).  In Sept.  2005,  he 
was diagnosed with a metastatic brain tumor of renal 
cell carcinoma by surgical resection.  To improve the 
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cerebral edema after surgical resection of the brain 
tumor,  we initiated corticosteroids (betamethasone 
5 mg daily for 7 days,  followed by betamethasone 
2 mg daily for 14 days,  and followed by betametha-
sone 1 mg daily for 14 days).  He was then treated 
with radiation therapy.  There was no evidence of dis-
ease other than the brain tumor.  A computed tomo-
graphic (CT) scan of the chest revealed mild emphyse-
matous changes but no bulla-like formations.
　 In Oct.  2005,  the patient presented a cough,  spu-
tum,  and high fever.  On physical examination,  he was 
comfortable and in no apparent distress.  Laboratory 
data revealed a white blood cell count of 8,300 cells 
per mm3 with a diﬀ erential of 78ｵ neutrophils and 
10ｵ lymphocytes,  and C-reactive protein (CRP) of 
14.6 mg/dl.  Chest radiography revealed inﬁ ltrative 
shadow throughout the right lung ﬁ eld.  A chest CT 
revealed multiple cystic lesions and alveolo-interstitial 
inﬁ ltrates in the right upper lobe (Fig.  1A).  
Empirical treatment with intravenous cefozopran 
2.0 g/day and minocycline 200 mg/day was initiated.
　 On hospital day 3,  the patient was still febrile,  and 
pulmonary inﬁ ltrates had increased.  Thus,  he was 
treated with intravenous meropenem 1.0 g/day and 
ciproﬂ oxacin 600 mg/day.  Sputum was repeatedly 
negative for malignant cells,  acid-fast bacilli,  asper-
gillus,  and candida.  Bacteriological investigation of 
blood culture also did not reveal any microorganism.  
An enzyme-linked immunosorbent assay (ELISA) test 
for HIV was negative.  However,  an aspergillus anti-
gen test in the serum done with an ELISA revealed 
positive results.  The antifungal therapy of micafungin 
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Fig. 1　　Chest CT scan showing cystic lesions and alveolo-interstitial inﬁ ltrates (A),  air-space consolidation with air crescent sign and 
ground glass attenuation after 10 days (B),  rapid progression of pulmonary inﬁ ltrates after 14 days (C),  and a thick-walled cavitary lesion 
suggestive of aspergilloma after 31 days (D).
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150 mg/day was started,  because it was unclear 
whether the pulmonary infection was secondary to 
invasive pulmonary aspergillosis.
　 On hospital day 10,  the patient was still febrile,  
and a chest CT revealed air-space consolidation with 
air crescent sign (Fig.  1B).  Micafungin was discontin-
ued,  and voriconazol was started.  On hospital day 14,  
the patient had persistent fever,  dyspnea,  and hypox-
emia (PaO2:50 mmHg,  measured with nasal oxygen 5 
L/min).  Chest radiographic ﬁ ndings revealed rapid 
progression of pulmonary inﬁ ltrates (Fig.  1C).  He 
developed an acute respiratory distress syndrome 
requiring mechanical ventilation and was transferred 
to the intensive care unit (ICU).
　 Voriconazol 300 mg/day was continued,  and an 
intravenous corticosteroid (methylprednisolone 1.0 g/
day) was started.  Transbronchial lung biopsy revealed 
necrotizing pneumonitis and numerous fungal hyphae.  
Septate fungal hyphae were identiﬁ ed extending into 
normal lung parenchyma.  Aspergillus fumigatus was 
isolated from a fungal culture of lung tissue.  
Moreover,  the diagnosis of pneumocystis jiroveci was 
made by bronchoalveolar lavage (BAL).  Combined 
IPA and PCP were diagnosed on hospital day 19.  
Thus,  trimethoprim/sulfamethoxazole 1,200 mg/day 
and an adjunctive corticosteroid (prednisolone 40 mg/
day) were initiated.
　 On hospital day 31,  chest CT revealed aspergil-
loma formation with a thin-walled cavity and improve-
ment of pulmonary inﬁ ltrates (Fig.  1D),  but the 
patient continued to require intubation.  His condition 
deteriorated,  and laboratory tests revealed the fol-
lowing: creatinine,  3.5 mg/dl; urea nitrogen,  79 mg/
dl; white blood cell count,  22,000/ｻl,  and C-reactive 
protein,  22.1 mg/dl.  On hospital day 58,  the patient 
died of multiple organ failure and sepsis.  His family 
declined permission for a post-mortem examination.
Discussion
　 The patient received short-term low doses of a 
steroid,  although brain metastasis due to renal cell 
carcinoma was controlled by the surgical resection and 
whole brain radiation therapy.  He was a non-HIV and 
cancer patient with COPD,  but there was no evidence 
of recurrence other than the brain tumor.  In the pres-
ent case,  therefore,  the major predisposing factors for 
IPA and PCP were considered to be steroid therapy.  
Rello et al.  described rapid progression of IPA in 
patients with COPD receiving low doses or a brief 
course of steroid therapy [4].  Cornet et al.  described 
that short-term systemic corticosteroid therapy in 
immunocompetent patients with underlying chronic 
lung conditions was a risk factor for IPA and,  fur-
thermore,  for its rapid evolution [5].  The number of 
cases reported among patients receiving brief steroid 
therapy has recently increased as awareness of the 
increased risk of IPA in these patients has grown [4,  
5].
　 In a retrospective analysis of the Mayo Clinic 
Rochester medical record registry [3],  among 30 
patients with acute respiratory failure due to non-
HIV-related PCP,  8 patients had received systemic 
corticosteroids only and 15 had received a combina-
tion of both corticosteroids and chemotherapy.  The 
median prednisone-equivalent dose and duration of 
corticosteroid use prior to diagnosis of PCP was 
40 mg (range,  5 to 200 mg) and 4.5 months (range,  
12 days to 25 months),  respectively.  Hematologic 
malignancies,  inﬂ ammatory diseases,  and solid malig-
nancies were the primary diagnoses present in the 
majority of patients,  accounting for 90ｵ of the 
underlying immunosuppressive conditions.  No patient 
was receiving prophylactic medications for PCP prior 
to the onset of pneumonia.  In addition to pneumocys-
tis,  aspergillus was detected in 2 of the 30 patients 
but was deemed to be secondary to microorganism 
colonization or a latent infection rather than an active 
disease.  Twenty-nine of the 30 patients required intu-
bation,  and 20 patients did not survive to discharge 
from the hospital,  yielding a mortality of 66.6ｵ.  The 
authors concluded that the delay in intubation on 
admission to the ICU was associated with a higher 
hospital mortality rate and that PCP prophylaxis 
should be strongly considered for all non-HIV immuno-
suppressed patients receiving prolonged systemic 
corticosteroid therapy.
　 Coinfection with aspergillus and pneumocystis jir-
oveci has been reported as a nosocomial complication 
in patients admitted to the ICU [1,  3].  In the present 
case,  both proven invasive microorganisms were com-
munity acquired.  However,  it was unclear whether 
pulmonary infection by aspergillus occurred prior to 
pneumocystis jiroveci.  The radiographic evaluation 
revealed pulmonary aspergillosis; however,  it was 
diﬃ  cult to make the radiographic diagnosis of com-
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bined IPA and PCP.  Early bronchoscopy with BAL 
should be considered in order to diagnose these oppor-
tunistic infections promptly.
　 Our case demonstrated that short-term systemic 
steroid therapy in non-HIV patients with underlying 
chronic lung conditions and malignancies was a risk 
factor for IPA and PCP,  and for a combination of 
these infections.  In such patients,  physicians should 
be alert to the fact that a high degree of suspicion is 
necessary for the diagnosis of these opportunistic 
infections.
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